prof. dr. M.G.E.H. (Marnix) Lam

Full Professor
prof. dr. M.G.E.H. (Marnix) Lam
  • Researchgr. Nucleaire Geneeskunde

Research Programs

Strategic Program Cancer



Marnix Lam (1975) studied Pharmaceutical sciences (passed with distinction) and Medicine at Utrecht University. He became a resident in Nuclear Medicine, respectively Radiology and finalized his PhD thesis (2009) on radionuclide therapy in prostate cancer patients with metastatic bone pain. This was followed by a two-year postdoctoral fellowship at Stanford University School of Medicine, USA. In 2016 he was appointed Professor of Nuclear Medicine.
Translational research in molecular medicine has been the scope of his scientific work, with a focus on oncology. Bringing new radiopharmaceuticals to clinical practice. This specifically resulted in the introduction of new oncological treatment modalities in the Netherlands, such as bone seeking radiopharmaceuticals for the palliation of metastatic bone pain (Sm-153-EDTMP, Re-188-HEDP) and radioembolization for treatment of hepatic malignancies (Y-90 and Ho-166 microspheres). Current research is focussed on dosimetry of therapeutic radiopharmaceuticals, image-guided treatment technology, alfa- and beta-emitting isotopes for therapeutic purposes, intra-arterial and intra-tumor treatment approaches, and radio-immunotherapy.

Side Activities

Board Member of the National Education Committee on Nuclear Medicine

National Coordinator on Education of Gastrointestinal Nuclear Medicine and Musculoskeletal Nuclear Medicine

Consultant for BTG and Terumo



Fellowship and Awards

Alavi-Mandell award for best publication in Journal of Nuclear Medicine: van den Hoven A, Rosenbaum C, Elias S, de Jong H, Koopman M, Verkooijen H, Alavi A, van den Bosch M, Lam MGEH. Insights into the dose-response relationship of radioembolization with resin yttrium-90 microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016 Jul;57(7):1014-9. (2017)

Research grant from the Dutch Cancer Society (KWF): Holmium-166 microspheres for radioembolization in HCC patients: new generation microspheres for individualized treatment (2016)

Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Prince JF, van Rooij R, Bol GH, de Jong HW, van den Bosch MA, Lam MGEH. Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres. J Nucl Med. 2015 Jun;56(6):817-23. (2016)

Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Blomberg BA, Thomassen A, de Jong PA, Simonsen JA, Lam MGEH, Nielsen AL, Mickley H, Mali WP, Alavi A5, Høilund-Carlsen PF. Impact of Personal Characteristics and Technical Factors on Quantification of Sodium 18F-Fluoride Uptake in Human Arteries: Prospective Evaluation of Healthy Subjects. J Nucl Med. 2015 Oct;56(10):1534-40. (2016)

Research grant from Alpe d’Huzes / Dutch Cancer Society (KWF): Holmium micro-brachytherapy: an innovative intratumoral treatment modality in head and neck cancer (2014)

Appointed as honorary professor at the medical school of the People’s Liberation Army General Hospital and Military University, Beijing, China (2014)

CIRSE Award of Excellence and Innovation in Interventional Radiology (2014)

Research grant from the Dutch Cancer Society (KWF): translational research in oncology (2010)

Research Output (203)

Gamma camera characterization at high holmium-166 activity in liver radioembolization

Stella M, Braat Arthur, Lam Marnix, de Jong Hugo, van Rooij Rob 2 mrt 2021, In: EJNMMI Phys. 8 , p. 22

Interventional respiratory motion compensation by simultaneous fluoroscopic and nuclear imaging:a phantom study

Dietze Martijn M A, Kunnen Britt, Lam Marnix G E H, de Jong Hugo W A M 11 feb 2021, In: Physics in medicine and biology. 66

Current Status and Future Direction of Hepatic Radioembolisation

Alsultan A A, Braat A J A T, Smits M L J, Barentsz M W, Bastiaannet R, Bruijnen R C G, de Keizer B, de Jong H W A M, Lam M G E H, Maccauro M, Chiesa C feb 2021, In: Clinical Oncology. 33 , p. 106-116 11 p.

Lung shunt and lung dose calculation methods for radioembolization treatment planning

Kappadath S Cheenu, Lopez Benjamin P, Salem Riad, Lam Marnix G 4 jan 2021, In: The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 65 , p. 32-42 11 p.

A Rapid and Safe Infusion Protocol for 177Lu Peptide Receptor Radionuclide Therapy.

Ebbers Sander C, Barentsz Maarten W, de Keizer Bart, Krijger Gerard C, Lam Marnix G E H, Braat Arthur J A T 27 nov 2020, In: Journal of Nuclear Medicine. 62 , p. 816-822 7 p.

The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer

Poot Alex J, Lam Marnix G E H, van Noesel Max M 19 nov 2020, In: Frontiers in oncology. 10 , p. 1-8

Lutetium-177 PSMA therapie voor patiënten met prostaatkanker – een kort overzicht van de literatuur

van Kalmthout Ludwike W.M., van der Sar Esmée C.A., Braat Arthur J.A.T., de Keizer Bart, Lam Marnix G.E.H. 1 okt 2020, In: Tijdschrift voor Urologie. 10 , p. 141-146 6 p.

Voorwoord bij het themanummer nucleaire geneeskunde:Theranostics voor diagnostiek en behandeling van prostaatkanker

van Kalmthout Ludwike W.M., Lam Marnix G.E.H. 1 okt 2020, In: Tijdschrift voor Urologie. 10 , p. 99-100 2 p.

PSMA PET/CT in de diagnostiek van primaire prostaatkanker:een samenvatting van de huidige literatuur

van der Sar Esmée C.A., van Kalmthout Ludwike M., Lam M. G.E.H. 1 okt 2020, In: Tijdschrift voor Urologie. 10 , p. 101-108 8 p.

Suppression of myocardial glucose metabolism in FDG PET/CT:impact of dose variation in heparin bolus pre-administration

Scholtens A M, van den Berk A M, van der Sluis N L, Esser J P, Lammers G K, de Klerk J M H, Lam M G E H, Verberne H J 1 okt 2020, In: European Journal of Nuclear Medicine and Molecular Imaging. 47 , p. 2698-2702 5 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet